Matt Judson

Matthew Judson is listed as a Managing Director - Mergers & Acquisitions at H.C. Wainwright & Co., LLC. FINRA/SEC broker-registration data mirrored by EPLICensed lists “MATTHEW JUDSON / MATT JUDSON” under H.C. Wainwright, CRD #2367272, with a start date of August 9, 2017.

Before H.C. Wainwright, The Org reports that Judson was a Managing Director at CRT Capital Group and Craig-Hallum Capital Group, where his work included co-heading healthcare investment banking. The same profile lists earlier experience at Leerink Partners, Robertson Stephens, Societe Generale Corporate & Investment Banking, Three Cities Research, and Bankers Trust Company.

His education is reported as a B.A. from the University of North Carolina at Chapel Hill, with prior attendance at Phillips Exeter Academy. His public LinkedIn profile also lists Phillips Exeter Academy and H.C. Wainwright & Co., LLC.

H.C. Wainwright describes itself as a full-service investment bank providing corporate finance, strategic advisory, research, sales and trading, and related services to public and private companies. Its investment banking business is especially visible in PIPE, registered direct, confidentially marketed public offering, and private-placement markets.

• Public evidence points to Judson primarily as an investment banker and M&A advisor, not as a currently active institutional VC or a publicly disclosed angel investor.
• His professional focus is M&A and strategic advisory, with a healthcare and life-sciences background from CRT Capital Group, Craig-Hallum, Leerink Partners, and H.C. Wainwright.
• H.C. Wainwright’s advisory practice says its expertise is in “small and mid-size market” advisory work and that it links clients with potential investors.
• H.C. Wainwright’s investment banking page says the firm executes equity offerings, debt issuances, derivative transactions, PIPEs, and registered direct offerings.
• The firm’s 2020 M&A advisory expansion announcement emphasized global M&A, public-private partnerships, licensing, capital-structure advisory, and support for life-sciences companies.